ABBV vs VRTX
AbbVie (ABBV) and Vertex Pharmaceuticals (VRTX) compared side by side. AbbVie (ABBV) is larger, with a market cap of $504.8B versus $132.8B for Vertex Pharmaceuticals, about 3.8 times the size. On trailing earnings, VRTX is cheaper at 29.9x versus 80.7x for ABBV.
Head to head
| Metric | ABBV | VRTX |
|---|---|---|
| Market cap | $504.8B | $132.8B |
| P/E (TTM) | 80.7x | 29.9x |
| Forward P/E | 17.6x | 25.7x |
| Revenue (TTM) | $64.4B | $12.6B |
| Revenue growth | 10.2% | 12.5% |
| Gross margin | 72.8% | 55.0% |
| Operating margin | 40.0% | 38.1% |
| Free cash flow | $18.2B | $3.8B |
| Dividend yield | 2.42% | None |
| 1-year return | +28.9% | +24.0% |
| 5-year return (annual) | +25.6% | +23.3% |
| Max drawdown | -45% | -92% |
| FI Handbook grade | B | B |
Highlighted: the stronger figure on metrics where higher or lower is clearly better.
Growth of $10,000 (5 years, price only)
ABBV vs VRTX FAQ
Which is bigger, ABBV or VRTX?
AbbVie (ABBV) is larger, with a market cap of $504.8B versus $132.8B for Vertex Pharmaceuticals, about 3.8 times the size.
Is ABBV or VRTX cheaper?
On trailing earnings, VRTX is cheaper at 29.9x versus 80.7x for ABBV. A lower P/E can reflect slower expected growth, so compare growth and margins too.
Which stock performed better over the past year, ABBV or VRTX?
ABBV returned +28.9% over the past year including dividends, versus +24.0% for VRTX, through October 23, 2026.
Which pays a higher dividend, ABBV or VRTX?
ABBV yields 2.42%; VRTX does not pay a dividend.
Full pages: AbbVie · Vertex Pharmaceuticals